跳至主要内容
临床试验/NCT00581191
NCT00581191终止1 期

Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SLV-351 Administered Orally to Healthy Subjects

Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 72 人开始时间: 2008年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
终止
发起方
入组人数
72
主要终点
Safet and tolerability

研究概览

简要总结

Safety and tolerability of single oral doses in healthy subjects.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Men, aged 18-50 years.
  • Women of nonchildbearing potential, aged 18-50 years.

排除标准

  • 未提供

研究组 & 干预措施

1

Experimental

0.5 mg SLV-351 (fasted)

干预措施: SLV-351 (Drug)

2

Experimental

1 mg SLV-351 (fasted)

干预措施: SLV-351 (Drug)

3

Experimental

2.5 mg SLV-351 (fasted)

干预措施: SLV-351 (Drug)

4

Experimental

5 mg SLV-351 (fasted)

干预措施: SLV-351 (Drug)

5

Experimental

10 mg SLV-351 (fasted)

干预措施: SLV-351 (Drug)

6

Experimental

15 mg SLV-351 (fasted)

干预措施: SLV-351 (Drug)

7

Experimental

20 mg SLV-351 (fasted)

干预措施: SLV-351 (Drug)

8

Experimental

30 mg SLV-351 (fasted)

干预措施: SLV-351 (Drug)

9

Experimental

xx mg SLV-351 (fasted and fed)

干预措施: SLV-351 (Drug)

结局指标

主要结局

Safet and tolerability

时间窗: 35 days

次要结局

  • PK and PD(35 days)

研究者

发起方
Wyeth is now a wholly owned subsidiary of Pfizer
申办方类型
Industry

相似试验

Study Evaluating the Safety and Tolerability of... | 临床试验